<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003782</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP B-30</org_study_id>
    <secondary_id>CDR0000066914</secondary_id>
    <nct_id>NCT00003782</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes</brief_title>
  <official_title>A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor
      cells remaining following surgery. It is not yet known which regimen of combination
      chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes.

      PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of
      combination chemotherapy in treating women who have undergone surgery for stage I, stage II,
      or stage IIIA breast cancer with positive axillary lymph nodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of adjuvant doxorubicin, cyclophosphamide, and docetaxel given
           concurrently vs adjuvant doxorubicin and cyclophosphamide followed by docetaxel, in
           terms of overall survival and disease-free survival, of women with breast cancer and
           positive axillary lymph nodes.

        -  Compare the efficacy of adjuvant doxorubicin and docetaxel vs regimens containing
           cyclophosphamide in these patients.

        -  Compare the toxic effects of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens. (Quality of life
           substudy closed to accrual as of 7/20/01.)

        -  Compare the differences in amenorrhea in premenopausal women in each treatment arm and
           its relationship to symptoms, quality of life (quality of life substudy closed to
           accrual as of 7/20/01), disease-free survival, and overall survival.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, number of positive nodes (1-3 vs 4-9 vs at least 10), sequential
      tamoxifen or anastrozole administration (yes vs no), and type of prior surgery and
      radiotherapy plan (mastectomy with no local or regional radiotherapy vs mastectomy with local
      and/or regional radiotherapy vs lumpectomy with local radiotherapy vs lumpectomy with local
      and regional radiotherapy). Patients are randomized to one of three treatment arms.

        -  Arm 1: Patients receive doxorubicin IV over 15 minutes and cyclophosphamide IV over 30
           minutes every 21 days for 4 courses. Three weeks after the last dose of this
           combination, patients receive docetaxel IV over 1 hour every 21 days for 4 courses.

        -  Arm 2: Patients receive doxorubicin IV over 15 minutes and docetaxel IV over 1 hour
           every 21 days for 4 courses.

        -  Arm 3: Patients receive doxorubicin IV over 15 minutes, cyclophosphamide IV over 30
           minutes, and docetaxel IV over 1 hour every 21 days for 4 courses.

      Patients in all arms who are estrogen receptor-positive and/or progesterone receptor-positive
      receive oral tamoxifen daily for 5 years beginning within 3-12 weeks of completion of
      chemotherapy. Patients who are postmenopausal may receive alternative hormonal therapy at the
      discretion of the treating physician.

      Some patients may receive postmastectomy radiotherapy on SWOG-S9927 or NCIC-MA.20 after
      recovery from chemotherapy.

      Quality of life and menstrual history are assessed before randomization, on day 1 of course
      4, and at 6, 12, 18, and 24 months. (Quality of life substudy closed to accrual as of
      7/20/01.)

      Patients are followed every 6 months for 5 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 5,300 patients will be accrued for this study within 4-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>time to event: breast cancer recurrence; second primary cancer; death from any cause as a first event</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities Among the 3 Regimens</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Among Breast Cancer Patients</measure>
    <time_frame>baseline, 9 weeks, and 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amenorrhea in Premenopausal Women</measure>
    <time_frame>baseline, 9 weeks, and 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5351</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin + Cyclophosphamide, then Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Doxorubicin + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin + Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin + Docetaxel + Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles</description>
    <arm_group_label>Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles</description>
    <arm_group_label>Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel</arm_group_label>
    <arm_group_label>Arm 2: Doxorubicin + Docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles</description>
    <arm_group_label>Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel</arm_group_label>
    <arm_group_label>Arm 2: Doxorubicin + Docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive adenocarcinoma of the breast

               -  Confined to the breast and ipsilateral axilla on clinical exam

                    -  Stage I, II, or IIIA (cT1-3, N0-1, M0)

          -  At least one axillary lymph node with evidence of tumor on histologic exam

               -  Sentinel node biopsy allowed if followed by axillary dissection

               -  No suspicious palpable nodes in the contralateral axilla or palpable
                  supraclavicular or infraclavicular nodes, unless proven on biopsy to not be
                  involved with tumor

          -  No bilateral malignancy or mass in the opposite breast, unless mass is histologically
             proven to be benign

          -  Must have undergone either a prior total mastectomy and axillary dissection (modified
             radical mastectomy) OR

          -  Prior lumpectomy and axillary dissection

               -  Patients must receive radiotherapy after randomization (not before) AND after
                  chemotherapy

               -  Margins must be clear

               -  No ipsilateral lymph nodes that are fixed to one another or to other structures
                  (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are
                  considered axillary nodes)

               -  No histologically evident invasive tumor or ductal carcinoma in situ

               -  No diffuse tumors by mammography that would not be surgically amenable to
                  lumpectomy

               -  No other dominant mass in the ipsilateral breast remnant unless one of the
                  following is true:

                    -  Histologically benign

                    -  Surgically removed with clear margins if malignant

          -  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude

               -  Tethering or dimpling of the skin or nipple inversion allowed

          -  No metastatic disease

               -  Skeletal pain allowed if bone scan negative for metastases

          -  Hormone receptor status:

               -  Estrogen and progesterone status determined

        PATIENT CHARACTERISTICS:

        Age:

          -  greater than or equal to 18 years

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 10 years, excluding diagnosis of cancer

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the
             investigator, this represents an ethnic or racial variation)

          -  Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper
             limit of normal (ULN), significant underlying hematologic disorders must be excluded

        Hepatic:

          -  Bilirubin no greater than ULN

          -  Alkaline phosphatase less than 2.5 times ULN*

          -  SGOT less than 1.5 times ULN*

          -  No nonmalignant systemic hepatic disease that would preclude study participation NOTE:
             *Alkaline phosphatase and SGOT cannot both be greater than ULN

        Renal:

          -  Creatinine no greater than normal

          -  No nonmalignant systemic renal disease that would preclude study participation

        Cardiovascular:

          -  No nonmalignant systemic cardiovascular disease that would preclude study
             participation

          -  LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram

          -  No active cardiac disease that would preclude use of doxorubicin or docetaxel,
             including the following:

               -  Any prior myocardial infarction

               -  Angina pectoris requiring anti-anginal medication

               -  History of congestive heart failure

               -  Cardiac arrhythmia requiring medication

               -  Severe conduction abnormality

               -  Valvular disease with documented cardiac function compromise

               -  Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at
                  least LLN

               -  Poorly controlled hypertension (diastolic greater than 100 mm/Hg)

               -  Hypertension well controlled by medication allowed

        Other:

          -  No grade 2 or greater peripheral neuropathy

          -  No other prior malignancy within the past 5 years except:

               -  Effectively treated squamous cell or basal cell skin cancer

               -  Surgically treated carcinoma in situ of the cervix

               -  Segmentally resected lobular carcinoma in situ of the ipsilateral or
                  contralateral breast

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  No nonmalignant systemic disease that would preclude study participation

          -  No diabetes with morning fasting blood glucose of 200 mg/dL or greater

          -  No psychiatric or addictive disorders that would preclude informed consent

          -  No contraindication to corticosteroids that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for breast cancer

        Chemotherapy:

          -  No prior chemotherapy for breast cancer

          -  No prior anthracyclines or taxanes

          -  No other concurrent investigational chemotherapy

        Endocrine therapy:

          -  No prior hormonal therapy for breast cancer

          -  No concurrent hormonal birth control methods or other hormonal therapy

          -  No concurrent raloxifene, including for osteoporosis

          -  Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or
             conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator
             applied vaginally 3 times a week) allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy for this malignancy

        Surgery:

          -  See Disease Characteristics

          -  No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy,
             mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy
             margins)

        Other:

          -  No prior systemic therapy for this malignancy

          -  No concurrent medications that alter cardiac conduction (e.g., digitalis, beta
             blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive
             heart failure (allowed if administered for other reasons [e.g., hypertension])

          -  Concurrent bisphosphonates allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99519-6604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Health Western Division Cancer Research Group</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center at Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Bay Area Tumor Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-3305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of the Desert</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic Healthcare West - Westbay Region</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107-1728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Santa Rosa Memorial Hospital</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program, Incorporated</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209-5031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Cancer Center at University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06360-7106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Howard University Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halifax Medical Center</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Atlanta Regional</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia Comprehensive Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dwight David Eisenhower Army Medical Center</name>
      <address>
        <city>Fort Gordon</city>
        <state>Georgia</state>
        <zip>30905-5650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Cancer Center</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-9985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian-St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creticos Cancer Center at Advocate Illinois Masonic Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Evanston</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center at Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46206-1367</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markey Cancer Center at University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-5070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Blood Disorders and Cancer</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center at Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center - Burlington</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkshire Medical Center</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute at Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075-9975</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Hospital Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-0250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Louis-Cape Girardeau</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southern Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - University of New Mexico HSC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. - Albany Regional Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical and Mental Health Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP-Our Lady of Mercy Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles R. Wood Foundation Cancer Center at Glens Falls Hospital</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center of University Health Systems of Eastern Carolina</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858-4354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104-4241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Merit Care Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital Cancer Center at Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital of Cincinnati, Incorporated</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Dayton</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Pointe Hospital - Cancer Care Center</name>
      <address>
        <city>Warrensville Heights</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-4772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Cancer Center - Scranton</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MainLine Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellspan Health - York Cancer Center</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Memphis at Baptist Memorial Hospital - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410-1894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Mountain Oncology Group</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates - Newport News</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Virginia Mason Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Oncology Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-0986</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304-1297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Camden-Clark Memorial Hospital</name>
      <address>
        <city>Parkersburg</city>
        <state>West Virginia</state>
        <zip>26102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L-4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement, Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009 Jan;113(2):315-20. doi: 10.1007/s10549-008-9937-0. Epub 2008 Feb 27.</citation>
    <PMID>18302020</PMID>
  </results_reference>
  <results_reference>
    <citation>Ganz PA, Land SR, Geyer CE, et al.: NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-76, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Swain SM, Jeong JH, Geyer CE, et al.: NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-75, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Swain SM, Land SR, Sundry R, et al.: Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) followed-by docetaxel (T) arm of NSABP B-30: preliminary results. [Abstract] J Clin Oncol 23 (Suppl 16): A-537, 13s, 2005.</citation>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>August 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2012</results_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel</title>
          <description>Doxorubicin + Cyclophosphamide, then Docetaxel</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Doxorubicin + Docetaxel</title>
          <description>Doxorubicin + Docetaxel</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</title>
          <description>Doxorubicin + Docetaxel + Cyclophosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1783"/>
                <participants group_id="P2" count="1784"/>
                <participants group_id="P3" count="1784"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1753"/>
                <participants group_id="P2" count="1753"/>
                <participants group_id="P3" count="1758"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow up data</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxorubicin + Cyclophosphamide, Then Docetaxel</title>
          <description>Doxorubicin + Cyclophosphamide, then Docetaxel</description>
        </group>
        <group group_id="B2">
          <title>Doxorubicin + Docetaxel</title>
          <description>Doxorubicin + Docetaxel</description>
        </group>
        <group group_id="B3">
          <title>Doxorubicin + Docetaxel + Cyclophosphamide</title>
          <description>Doxorubicin + Docetaxel + Cyclophosphamide</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1783"/>
            <count group_id="B2" value="1784"/>
            <count group_id="B3" value="1784"/>
            <count group_id="B4" value="5351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="9.8"/>
                    <measurement group_id="B2" value="50" spread="9.5"/>
                    <measurement group_id="B3" value="51" spread="9.9"/>
                    <measurement group_id="B4" value="51" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1783"/>
                    <measurement group_id="B2" value="1784"/>
                    <measurement group_id="B3" value="1784"/>
                    <measurement group_id="B4" value="5351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel</title>
            <description>Doxorubicin + Cyclophosphamide, then Docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Doxorubicin + Docetaxel</title>
            <description>Doxorubicin + Docetaxel</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide</title>
            <description>Doxorubicin + Docetaxel + Cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>percentage of patients alive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1753"/>
                <count group_id="O2" value="1753"/>
                <count group_id="O3" value="1758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival</title>
        <time_frame>time to event: breast cancer recurrence; second primary cancer; death from any cause as a first event</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicities Among the 3 Regimens</title>
        <time_frame>9 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Among Breast Cancer Patients</title>
        <time_frame>baseline, 9 weeks, and 6, 12, 18, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amenorrhea in Premenopausal Women</title>
        <time_frame>baseline, 9 weeks, and 6, 12, 18, and 24 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants at Risk includes any patient who submitted an AE form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxorubicin + Cyclophosphamide, Then Docetaxel</title>
          <description>Doxorubicin + Cyclophosphamide, then Docetaxel</description>
        </group>
        <group group_id="E2">
          <title>Doxorubicin + Docetaxel</title>
          <description>Doxorubicin + Docetaxel</description>
        </group>
        <group group_id="E3">
          <title>Doxorubicin + Docetaxel + Cyclophosphamide</title>
          <description>Doxorubicin + Docetaxel + Cyclophosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST/SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="845" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="561" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="641" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="383" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="275" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1745"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1748"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1748"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1745"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Division of Regulatory Affairs</name_or_title>
      <organization>NSABP Foundation, Inc.</organization>
      <phone>412-330-4600</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

